Skip to content
Head to head

Elanco Animal Health vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: ELAN · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

ELAN +20.2%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
ELANTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price25.7421.77
Change today-2.09%+1.68%
1-year return+21.2%+57.5%
Market cap$12.87B$69.76B
52-week range19.40 – 27.9813.92 – 22.07
Valuation
P/E (TTM)-85.80311.00
P/E percentile, own 5-yr range5th100th
P/B1.941.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)-0.47-0.30
Net profit (TTM)$-234.92M$-970.94M
Revenue (TTM)$5.15B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+11.3%+6.7%
Gross margin56.2%65.8%
Operating margin7.6%14.3%
Net margin-2.9%0.9%
Free cash flow (TTM)$408.00M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership111.9%51.3%
Insider activity (12mo)48 buy / 2 sell19 buy / 31 sell
Short interest (% of float)6.6%0.1%
Analyst consensus82% buy / 18% hold (11)100% buy (1)
Analyst price target$31 (+20%)$50 (+132%)
StockVane view
StockVane Quant RatingC (65)C (90)
Company
Employees9,40047,029
Founded19541781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.